PMID- 14632961
OWN - NLM
STAT- MEDLINE
DCOM- 20040224
LR  - 20191026
IS  - 0269-4727 (Print)
IS  - 0269-4727 (Linking)
VI  - 28
IP  - 5
DP  - 2003 Oct
TI  - The role of low-molecular-weight heparins in cardiovascular medicine.
PG  - 371-8
AB  - Low-molecular-weight heparins (LMWHs) have been shown to be as effective and safe 
      as unfractionated heparin (UFH) for acute phase treatment of acute coronary 
      syndrome in the absence of ST-elevation [unstable angina/non-ST-elevation 
      myocardial infarction (UA/NSTEMI)]. LMWHs have practical advantages over UFH, 
      including usual lack of requirement for laboratory monitoring of the 
      anticoagulant response because of their favourable pharmacokinetic properties, 
      and thus represent a simpler and more cost-effective option in clinical practice. 
      The LMWH dalteparin has been shown to provide extended therapy benefit to 
      high-risk UA/NSTEMI patients and can provide a protective bridge until 
      revascularization. While revascularization procedures are now an established 
      intervention for patients with UA/NSTEMI, a new approach for patients who cannot 
      undergo immediate catheter intervention is to continue with medical treatment 
      until revascularization is possible. LMWHs are currently being investigated for 
      use in the catheterization laboratory, in patients undergoing percutaneous 
      coronary intervention procedures, and in conjunction with thrombolytics for 
      treatment of acute myocardial infarction.
FAU - Hodl, R
AU  - Hodl R
AD  - Division of Cardiology, Department of Medicine, Karl-Franzens University, Graz, 
      Austria. ronald.hoedl@kfunigraz.ac.at
FAU - Klein, W
AU  - Klein W
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Angina, Unstable/*drug therapy
MH  - Anticoagulants/*therapeutic use
MH  - Coronary Disease/*drug therapy
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Randomized Controlled Trials as Topic
RF  - 54
EDAT- 2003/11/25 05:00
MHDA- 2004/02/26 05:00
CRDT- 2003/11/25 05:00
PHST- 2003/11/25 05:00 [pubmed]
PHST- 2004/02/26 05:00 [medline]
PHST- 2003/11/25 05:00 [entrez]
AID - 504 [pii]
AID - 10.1046/j.0269-4727.2003.00504.x [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2003 Oct;28(5):371-8. doi: 10.1046/j.0269-4727.2003.00504.x.